Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMPART
2024-513219-29-00Phase 3Authorised
- Sponsor
- University College London
- Start
- Oct 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 3, randomised trial of durvalumab and tiragolumab in renal cell carcinoma (RCC) (3 arms), sponsored by University College London. Primary endpoints: Disease-free survival and Overall survival. Planned start Oct 2024; status: authorised.
02
Drugs
durvalumabtiragolumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2024-513219-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513219-29-00.